Pragma Bio

Pragma Bio is a private, preclinical-stage biotech based in San Diego, pioneering a novel drug discovery paradigm centered on the gut-immune axis. The company's proprietary PIKASO platform integrates bioinformatics, AI, synthetic biology, and pharmacology to mine, synthesize, and test gut-derived small molecules from biosynthetic gene clusters. With backing from top-tier investors and a seasoned leadership team, Pragma Bio is building a pipeline of new chemical entities aimed at addressing high-failure-rate areas in traditional drug development, though it faces significant scientific and competitive risks inherent to the emerging microbiome therapeutics field.

PIKASO: An end-to-end, AI-enabled platform integrating bioinformatics/AI (to mine clinically-relevant Biosynthetic Gene Clusters), synthetic biology/medicinal chemistry (to synthesize and optimize novel small molecules), and pharmacology (for phenotypic testing and target deconvolution).

Pragma Bio competes in the broader microbiome therapeutics space, which includes companies developing live biotherapeutic products (e.g., Seres Therapeutics, Vedanta Biosciences), purified metabolites (e.g., Finch Therapeutics), and other small-molecule discoverers (e.g., Second Genome, whose founder is an advisor). Its key differentiation is its integrated AI/ML-driven platform focused exclusively on mining and synthesizing novel small molecules from human microbiome BGCs, a niche with fewer established players.